1. Disclaimer
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
This article is intended for general educational and informational purposes only. It does not replace current local prescribing information, professional medical advice, diagnosis, monitoring, or individualized treatment. Product composition, approved indication, contraindications, dose ranges, manufacturer details, package sizes, and marketing authorization may differ by country and may change over time. The current Egyptian carton, package leaflet, and the relevant regulatory information should be checked before prescribing, dispensing, or using this medicine.
2. Summary
Cardivo-Care / Cardivocare® is an oral fixed-dose antihypertensive combination containing bisoprolol fumarate, a predominantly beta1-selective adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic. The two components lower blood pressure through complementary mechanisms: bisoprolol reduces heart rate, cardiac output, and renin release, while hydrochlorothiazide increases renal sodium and chloride excretion and, with continued treatment, contributes to a reduction in peripheral vascular resistance.[2]
The supplied historical Egyptian leaflet describes two film-coated tablet strengths: 10 mg/6.25 mg and 5 mg/12.5 mg of bisoprolol fumarate/hydrochlorothiazide. A current manufacturer-hosted Egyptian product page identifies Cardivocare 5 mg/12.5 mg; however, the current Egyptian carton and leaflet remain the authoritative source for the local strengths, pack size, manufacturer, and marketing-authorisation details.[1]
This combination is used for hypertension. It is not an acute treatment for a hypertensive emergency, and it should not be stopped abruptly without medical supervision because withdrawal of the beta-blocking component can worsen angina or, in susceptible patients, precipitate serious cardiovascular events.[2]
3. Brand Name
Cardivo-Care / Cardivocare®
The supplied historical documents use the spelling Cardivo-Care, whereas the current manufacturer-hosted Egyptian product page uses Cardivocare®. These names are presented here as the same locally marketed brand family, but the actual product name on the current Egyptian package should be used for publication and dispensing verification.[1]
4. Category
- Antihypertensive combination product
- Beta-blocker plus thiazide diuretic
- Bisoprolol: predominantly beta1-selective (cardioselective) adrenergic receptor blocker
- Hydrochlorothiazide: thiazide diuretic
5. Active Ingredients
| Ingredient | Pharmacological role |
|---|---|
| Bisoprolol fumarate | Predominantly beta1-selective adrenergic receptor blocker. |
| Hydrochlorothiazide | Thiazide diuretic that acts on renal tubular electrolyte reabsorption. |
Bisoprolol fumarate is the salt form used in the tablet. Hydrochlorothiazide is a benzothiadiazine diuretic. Neither component should be confused with a medicine intended to provide immediate treatment of chest pain, an acute heart-failure episode, or a hypertensive emergency.[2]
6. Pharmaceutical Form & Strength
Pharmaceutical form: Film-coated tablets for oral use.
| Strength described in the supplied information | Composition per film-coated tablet | Verification note |
|---|---|---|
| Cardivo-Care 10/6.25 mg | Bisoprolol fumarate 10 mg + hydrochlorothiazide 6.25 mg | Described in the supplied historical leaflet. Current local availability should be checked from the carton and current Egyptian product information. |
| Cardivo-Care 5/12.5 mg | Bisoprolol fumarate 5 mg + hydrochlorothiazide 12.5 mg | Described in the supplied historical leaflet; a manufacturer-hosted Egyptian page identifies Cardivocare 5/12.5 mg.[1] |
The historical leaflet reports packs containing 10, 20, or 30 film-coated tablets. Because pack presentations and product registrations can change, the current package should be checked rather than treating historical pack data as current.
7. Manufacturer & Marketing Authorization Holder
The supplied historical leaflet states:
Produced by Arab Caps for Gelatin & Pharmaceutical Products for Pharmacare Egypt for Trading Agency.
A current manufacturer-hosted Egyptian cardiovascular-product page displays Cardivocare 5/12.5 mg and refers to Pharmacare products, but an accessible official source sufficient to verify the exact current Egyptian manufacturer and Marketing Authorization Holder (MAH) for both Cardivo-Care strengths was not identified during this review.[1]
Accordingly, the historical Arab Caps/Pharmacare statement should be treated as historical product information. The current Egyptian carton, package leaflet, and national regulatory record should be used to confirm the manufacturer, batch release site, MAH, registration status, and current pack presentations.
8. Mechanism of Action
Bisoprolol fumarate
Bisoprolol is predominantly beta1-selective at therapeutic doses. Beta1 blockade produces a negative chronotropic effect, thereby reducing resting and exercise heart rate. Its antihypertensive activity is thought to involve reduced cardiac output, inhibition of renal renin release, and reduced sympathetic outflow. At higher doses, beta1-selectivity becomes less absolute, so bronchial beta2 blockade may become clinically relevant in susceptible people.[2]
Hydrochlorothiazide
Hydrochlorothiazide acts mainly at the distal renal tubule, increasing urinary sodium and chloride excretion. The resulting natriuresis can lead to secondary potassium loss. With longer-term use, reduced peripheral vascular resistance contributes to blood-pressure lowering.[2]
Combination effect
The antihypertensive effects of bisoprolol and hydrochlorothiazide are additive. A fixed-dose combination can simplify therapy when a clinician has determined that both components are appropriate, but it also means that contraindications, interactions, and adverse effects of both medicines must be considered.[2]
9. Spectrum of Activity
Not applicable in the antimicrobial sense. Cardivo-Care is not an antibiotic, antiviral, antifungal, or antiparasitic medicine. Its pharmacological activity is directed at blood-pressure control through cardiovascular and renal mechanisms.
10. Pharmacokinetics
| Parameter | Bisoprolol fumarate | Hydrochlorothiazide |
|---|---|---|
| Absorption | Well absorbed orally; absolute bioavailability after a 10 mg oral dose is approximately 80% in the reviewed official label. | Well absorbed orally; reported absorption is approximately 65%–75%. |
| Time to peak concentration in a combination tablet | Approximately 3 hours in the reviewed 2.5/6.25, 5/6.25, and 10/6.25 mg combination products. | Approximately 2.5 hours in the reviewed combination product. |
| Elimination | Eliminated through renal and non-renal pathways; approximately half of the dose is excreted unchanged in urine. | Eliminated mainly by the kidneys, predominantly unchanged. |
| Half-life | Approximately 7–15 hours for the reviewed combination; longer in significant renal impairment and may be prolonged in cirrhosis. | Approximately 4–10 hours in the reviewed combination; prolonged in renal impairment. |
In the reviewed U.S. combination product, food did not alter the bioavailability of either component. This should not replace the local Cardivo-Care leaflet, which should be followed for the Egyptian product’s specific administration instructions.[2]
11. Indications
Primary verified therapeutic use: treatment/management of hypertension.[1] [2]
The supplied historical leaflet describes use for mild to moderate hypertension. The precise indication, whether use is appropriate as initial therapy or after inadequate control with one component, and the approved strength-specific labeling must be determined from the current Egyptian prescribing information.
12. Administration
Route: Oral.
The supplied historical leaflet states that the dose is individualized and that the usual dose is one tablet once daily. It states that tablets should be taken in the morning before, during, or after breakfast, swallowed with a little liquid, and not chewed.
The dose and strength must be selected by the prescriber according to blood pressure, heart rate, kidney function, electrolyte status, concurrent medicines, and tolerability. Do not increase, reduce, skip repeatedly, or stop treatment independently.
The current U.S. combination label uses different strengths from the local product and recommends individualization; it describes a low-dose 2.5/6.25 mg starting regimen with titration at 14-day intervals for that product. This is not a Cardivo-Care-specific dosing instruction and must not be used to replace the current Egyptian leaflet or a clinician’s instructions.[2]
Discontinuation: The beta-blocker component should not be stopped suddenly. In patients with coronary artery disease, abrupt beta-blocker withdrawal has been associated with worsening angina and, in some cases, myocardial infarction or ventricular arrhythmia. If treatment must be withdrawn, a clinician should direct gradual tapering.[2]
13. Method of Preparation
Not applicable. Cardivo-Care is supplied as a ready-to-use oral film-coated tablet. No reconstitution or dilution is required.
Tablets should be swallowed whole with liquid and should not be chewed unless the current local product information specifically states otherwise.
14. Contraindications
Contraindications may differ between national labels. The following are contraindications in the current official U.S. bisoprolol/hydrochlorothiazide combination label reviewed:
- Cardiogenic shock.
- Overt cardiac failure.
- Second- or third-degree atrioventricular block.
- Marked sinus bradycardia.
- Anuria.
- Hypersensitivity to either component or to other sulfonamide-derived drugs.
The supplied historical leaflet also listed uncontrolled heart failure, significant bradycardia below 50 beats/minute, conduction disorders or sick sinus syndrome, severe bronchial asthma, Prinzmetal’s angina, untreated pheochromocytoma, severe peripheral arterial disease including Raynaud’s syndrome, hypotension, severe renal or hepatic impairment, breastfeeding, and combination with lithium or certain medicines that increase the risk of rhythm disturbances.
Several of these historical items remain clinically important cautions or restrictions, but the current official combination label does not word all of them as universal absolute contraindications. The locally approved Cardivo-Care leaflet should be treated as authoritative for the Egyptian contraindication list.
15. Warnings & Precautions
Heart failure, bradycardia, conduction disorders, and hypotension
Bisoprolol can slow heart rate and atrioventricular conduction. It may worsen existing conduction disease, cause symptomatic bradycardia, or contribute to hypotension. Patients with signs of heart failure, such as increasing shortness of breath, sudden weight gain, swelling, or marked fatigue, require clinical assessment.[2]
Do not stop abruptly
Never stop Cardivo-Care suddenly without medical advice, particularly in ischemic heart disease. A supervised gradual reduction is generally required.[2]
Respiratory disease
Although bisoprolol is relatively beta1-selective, selectivity is not absolute. Beta-blockers are generally avoided in bronchospastic disease unless a clinician considers the expected benefit to outweigh the risk. The lowest effective dose and appropriate access to bronchodilator therapy may be important when use is unavoidable.[2]
Diabetes, fasting, and hypoglycemia
Beta-blockers can mask early adrenergic warning signs of hypoglycemia, particularly tachycardia. The thiazide component may also affect glucose control. In 2025, EMA pharmacovigilance authorities recommended updated product information because concurrent beta-blocker and sulfonylurea use may increase the risk of severe hypoglycemia; patients using sulfonylureas should monitor blood glucose carefully.[3]
Kidney function, liver disease, and electrolytes
Hydrochlorothiazide can cause fluid or electrolyte disturbances, including hyponatremia, hypokalemia, hypomagnesemia, and hypochloremic alkalosis. It can also increase uric acid and precipitate gout. Renal impairment may increase exposure to both components, while hepatic impairment can increase clinical risk and slow bisoprolol elimination. Periodic clinical and laboratory monitoring may be appropriate, especially after initiation or dose changes and in patients at increased risk.[2]
Acute eye symptoms
Hydrochlorothiazide, a sulfonamide, can rarely cause acute myopia and acute angle-closure glaucoma, sometimes with choroidal effusions. Acute decreased vision or eye pain, particularly within hours to weeks after starting treatment, requires urgent medical assessment; discontinuation of hydrochlorothiazide may be necessary.[2]
Photosensitivity and non-melanoma skin cancer
Hydrochlorothiazide can cause photosensitivity. Regulatory labeling also warns of an association between cumulative hydrochlorothiazide exposure and non-melanoma skin cancer. Patients should limit excessive sunlight and ultraviolet exposure, use appropriate sun protection, check for new or changing skin lesions, and seek medical advice for suspicious lesions. The treatment plan may need reassessment in people with a history of non-melanoma skin cancer.[4] [5]
Peripheral vascular disease, thyroid disease, gout, psoriasis, and surgery
The supplied historical leaflet advises particular caution in heart disease, arterial disease including Raynaud’s syndrome, chronic bronchial disease, diabetes, thyroid disorders, gout, psoriasis, renal impairment, and during desensitization therapy. These are clinically relevant considerations. Before surgery, the anesthetist should be informed that the patient is taking a beta-blocker. Chronically administered beta-blocker therapy should not normally be stopped routinely before major surgery, but perioperative management must be individualized.[2]
16. Drug Interactions
| Interacting medicine or class | Potential concern |
|---|---|
| Lithium | Thiazide diuretics can reduce lithium renal clearance and increase the risk of lithium toxicity. Concomitant use is generally avoided unless specifically managed by a clinician.[2] |
| Verapamil, diltiazem, certain antiarrhythmics, or digitalis glycosides | Additive slowing of heart rate or AV conduction; increased risk of bradycardia, conduction disturbance, or cardiac depression.[2] |
| Clonidine | Withdrawal requires careful sequencing. The beta-blocker is generally withdrawn before clonidine to reduce the risk of rebound effects; this must be clinician-directed.[2] |
| Other antihypertensives, alcohol, barbiturates, or opioids | Additive blood-pressure lowering and increased risk of orthostatic hypotension.[2] |
| NSAIDs | May reduce the diuretic, natriuretic, and antihypertensive effects of hydrochlorothiazide; blood pressure and kidney function may need monitoring.[2] |
| Insulin, oral antidiabetic medicines, and especially sulfonylureas | Glucose control may change; beta-blockers can mask hypoglycemia warning signs, and EMA’s 2025 update highlights a possible increased risk of severe hypoglycemia with sulfonylureas.[3] |
| Cholestyramine or colestipol | Can reduce hydrochlorothiazide absorption.[2] |
| Corticosteroids or ACTH | May intensify electrolyte depletion, particularly hypokalemia.[2] |
| Rifampicin | Can increase bisoprolol metabolic clearance and shorten its half-life.[2] |
This is not a complete interaction list. The patient should provide a complete medication list, including non-prescription medicines and supplements, to the prescriber and pharmacist.
17. Side Effects
Not every listed reaction occurs, and frequency may vary by strength, dose, patient characteristics, and local product labeling.
More commonly reported or clinically relevant effects
- Tiredness, fatigue, weakness, dizziness, headache, or reduced exercise tolerance.
- Slow heart rate, low blood pressure, orthostatic symptoms, cold or numb extremities, and peripheral circulatory complaints.
- Nausea, vomiting, diarrhea, constipation, dyspepsia, or abdominal discomfort.
- Muscle cramps or laboratory electrolyte abnormalities.
- Increased uric acid or gout.
- Changes in kidney function, especially in people with pre-existing renal impairment or volume depletion.
Potentially serious effects requiring prompt medical assessment
- Fainting, marked bradycardia, severe dizziness, chest pain, new/worsening shortness of breath, or signs of heart failure.
- Wheezing or bronchospasm, particularly in people with asthma or obstructive airway disease.
- Severe rash, swelling of the face or throat, anaphylaxis, or serious skin reactions.
- Symptoms of electrolyte disturbance, such as severe weakness, confusion, persistent vomiting, severe muscle cramps, or palpitations.
- Acute eye pain or sudden reduced vision.
- Symptoms suggestive of liver disease, such as unexplained nausea, marked fatigue, dark urine, or jaundice.
The historical leaflet notes peripheral circulatory problems, tiredness/exhaustion/dizziness/headache, gastrointestinal problems, increased gout risk, bradycardia, conduction disturbances, orthostatic hypotension, breathing problems in susceptible people, and kidney-function disturbance. These remain clinically plausible effects of the component medicines and should be interpreted in the context of the current local leaflet.[2]
18. Use in Special Populations
Pregnancy
The supplied historical leaflet states that use in pregnancy is not recommended. Current official combination labeling states that the medicine should be used during pregnancy only if the anticipated benefit justifies the potential fetal risk. Thiazides cross the placenta and may be associated with fetal or neonatal adverse effects. A clinician should assess the individual situation and current local pregnancy labeling before use.[2]
Breastfeeding
The historical leaflet advises against breastfeeding. Current official combination labeling states that bisoprolol/hydrochlorothiazide has not been studied in nursing mothers and that a decision should be made whether to discontinue breastfeeding or discontinue the drug, considering the medicine’s importance to the mother. The current Egyptian leaflet should be followed.[2]
Children and adolescents
Safety and effectiveness of the reviewed bisoprolol/hydrochlorothiazide combination have not been established in pediatric patients. Do not use in children unless a specialist has prescribed the locally approved product for a specific reason.[2]
Older adults
The historical leaflet advises caution in older adults. Dose adjustment based on age alone is not usually required in the reviewed international label, but kidney function, liver function, comorbidity, fall risk, blood pressure, pulse, hydration status, and concurrent medicines require careful assessment.[2]
Renal or hepatic impairment
Use and titration require caution in renal dysfunction or hepatic impairment. The historical leaflet listed severe renal or hepatic impairment as a contraindication; the current local product label should determine whether a given level of impairment is a formal contraindication, a reason for avoidance, or a reason for lower-dose treatment and closer monitoring.
19. Storage Conditions
The supplied historical Cardivo-Care leaflet states: Do not store above 25°C. Do not use after the expiry date stated on the tablet.
Because storage requirements and packaging can change by product and market, the storage conditions printed on the current Egyptian carton and leaflet should take precedence. Keep medicines out of the reach and sight of children.
20. Additional Sections
Monitoring considerations
Depending on the patient and treatment plan, clinicians may monitor blood pressure, pulse, kidney function, serum electrolytes (especially sodium, potassium, and magnesium), uric acid, and glucose. Monitoring is particularly relevant after initiation or dose adjustment, during illness causing dehydration or vomiting, when interacting medicines are added, and in people with diabetes, gout, kidney disease, liver disease, or older age.[2]
Overdose
Overdose can cause bradycardia, hypotension, lethargy, heart block, heart failure, bronchospasm, hypoglycemia, dehydration, and electrolyte loss. It requires urgent medical evaluation and supportive treatment; no specific self-treatment is appropriate. The historical leaflet and any medicine packaging should be taken to the emergency service if possible.[2]
What to do if a dose is missed
Patients should follow the instructions in the current leaflet or contact the prescriber or pharmacist. They should not take a double dose to compensate for a missed dose unless specifically instructed by a healthcare professional.
21. Frequently Asked Questions (FAQ)
1. Is Cardivo-Care used for hypertension?
Yes. Bisoprolol/hydrochlorothiazide fixed-dose combinations are used for hypertension. The locally approved Cardivo-Care indication and strength should be verified from the current Egyptian leaflet.[1] [2]
2. Is Cardivo-Care an emergency treatment for very high blood pressure?
No. It is a maintenance antihypertensive medicine and is not intended for self-treatment of a hypertensive emergency.
3. Can the tablet be stopped when blood pressure becomes normal?
No. Blood pressure control while taking treatment does not mean the underlying condition has resolved. Bisoprolol-containing treatment should not be stopped abruptly without a clinician’s plan.[2]
4. Can a person with asthma take Cardivo-Care?
Bisoprolol is relatively beta1-selective, but this selectivity is incomplete. People with asthma or bronchospastic disease require individual clinical assessment; they should not start or continue treatment without medical advice.[2]
5. Why is blood testing sometimes needed?
Hydrochlorothiazide can affect electrolytes, kidney function, uric acid, and glucose. Monitoring helps identify clinically important changes.[2]
6. Can Cardivo-Care be taken with lithium?
Generally, thiazide diuretics and lithium should not be combined without specialist supervision because hydrochlorothiazide can increase the risk of lithium toxicity.[2]
7. Does the medicine increase sun sensitivity?
Hydrochlorothiazide can cause photosensitivity. Sun and ultraviolet protection is advisable, and new or changing skin lesions should be evaluated.[4] [5]
8. Can people with diabetes use Cardivo-Care?
It may be used when prescribed, but glucose monitoring is important. Bisoprolol may mask some hypoglycemia warning signs, and concurrent sulfonylurea treatment may increase the risk of severe hypoglycemia.[3]
9. What if there is sudden eye pain or blurred vision after starting treatment?
Seek urgent medical assessment. Hydrochlorothiazide has been associated with rare acute myopia and angle-closure glaucoma reactions.[2]
10. Are the 10/6.25 mg and 5/12.5 mg products interchangeable?
No. They contain different amounts of both components. Switching strengths or brands must be directed by the prescriber and verified against the current local product information.
22. References
- Multicare Egypt. Cardiovascular product page: Cardivocare 5/12.5 mg. Accessed 11 August 2026.
- DailyMed (U.S. National Library of Medicine). Bisoprolol fumarate and hydrochlorothiazide tablets, film coated: official prescribing information. Revised May 2026.
- European Medicines Agency. Bisoprolol/hydrochlorothiazide: CMDh scientific conclusions and product-information amendments. July 2025.
- DailyMed (U.S. National Library of Medicine). Hydrochlorothiazide tablets: official prescribing information. Updated October 2025.
- European Medicines Agency. PRAC product-information wording: hydrochlorothiazide and non-melanoma skin cancer. October 2018.
- Supplied historical Cardivo-Care leaflet: product identity, historical 10/6.25 mg and 5/12.5 mg formulations, administration wording, historical contraindications, adverse effects, packaging, storage, and Arab Caps/Pharmacare statement. Historical information was cross-checked against current class-level regulatory sources and retained only with appropriate current-label caveats.